
    
      The study will include a screening period up to 4 weeks and a 12- week treatment period. The
      overall study duration for participants will be approximately 16 weeks. Study participants
      will undergo physical and gynecological exams, and blood tests for clinical laboratory
      assessments. All patients with a uterus will undergo transvaginal ultrasound.
    
  